Hengrui Pharmaceuticals

Explore the latest insights on Hengrui Pharmaceuticals and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Hengrui Pharmaceuticals’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Others

Sino Biopharm’s CTTQ Wins China’s First Generic Approval for TQC3403 Umeclidinium/Vilanterol Inhaler – Head‑to‑Head Phase III Equivalence Backs COPD Maintenance Launch

Sino Biopharmaceutical Limited (HKG: 1177) announced that TQC3403, a umeclidinium bromide/vilanterol inhalation powder aerosol independently developed by its subsidiary Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), has been approved…

October 23, 2026

Harbour BioMed’s Batoclimab Wins NMPA Marketing Approval in China – First‑Class FcRn Antibody Now Indicated for AChR‑Positive Generalized Myasthenia Gravis

October 23, 2026

Merck’s Welireg (belzutifan) Wins NMPA Approval in China for Pheochromocytoma and Paraganglioma – Second Chinese Indication for the First‑in‑Class HIF‑2α Inhibitor

October 23, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.

Explore Now

Company Drug

Hengrui Pharmaceuticals

Sino Biopharm’s CTTQ Wins China’s First Generic Approval for TQC3403 Umeclidinium/Vilanterol Inhaler – Head‑to‑Head Phase III Equivalence Backs COPD Maintenance Launch

Harbour BioMed’s Batoclimab Wins NMPA Marketing Approval in China – First‑Class FcRn Antibody Now Indicated for AChR‑Positive Generalized Myasthenia Gravis

Merck’s Welireg (belzutifan) Wins NMPA Approval in China for Pheochromocytoma and Paraganglioma – Second Chinese Indication for the First‑in‑Class HIF‑2α Inhibitor

Empowering Chinese Pharma’s Global Expansion

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Hengrui Resubmits Camrelizumab-Apatinib BLA for HCC to FDA

Hengrui Ruitanning Gets NMPA Nod for Moderately Emetogenic Chemo Indication

Hengrui Cancer Combo Gets NMPA Nod for Liver Cancer Trials

Hengrui’s HRS-5346 Lp(a) Inhibitor Gets China Breakthrough Therapy Designation in $1.97B Merck Deal

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Hengrui’s SHR-9839 + HRS-4642 Combo Cleared for Advanced CRC Trials

Hengrui’s SHR‑1826 ADC Earns Breakthrough Therapy Designation for c‑Met Overexpressed NSCLC

About Company